Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Faeth Therapeutics granted options for 68,000 shares to three new hires under its 2026 Inducement Plan. The Compensation Committee approved the awards to attract talent. These stock options became effective on November 4, 2026, as part of the company's standard employment incentives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth granted options to three new employees.
  • A total of 68,000 shares were awarded.
  • The options are part of the 2026 Inducement Plan.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~40 mo
Low dilution risk
Lead asset
Serabelisib
Phase 2 · HR+ HER2- Breast Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective November 4, 2026 pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment w

Frequently Asked Questions

What did Faeth Therapeutics announce?

Faeth announced the granting of stock options to three new employees.

How many shares were granted?

A total of 68,000 shares were awarded to the new employees.

When are the options effective?

The options are effective from November 4, 2026.

What is the purpose of the Option Awards?

The awards serve as a material inducement for new hires.

Last updated: Nov 5, 2026